12. Zheng H, Koo EH (2011) Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 6: 27. 13. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 297: 353–356. 14. Marcello E, Epis R, Saraceno C, Di Luca M (2012) Synaptic dysfunction in Alzheimer’s disease. Adv Exp Med Biol 970: 573–601. 15. Koffie RM, Hyman BT, Spires-Jones TL (2011) Alzheimer’s disease: synapses gone cold. Mol Neurodeg 6: 63–72. 16. Benilova I, Karran E, De Strooper B (2012) The toxic aß oliogmer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15: 349–357. 17. Dyrks T, Weidemann A, Multhaup G, Salbaum JM, Lemaire HG, et al. (1988) Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer’s disease. EMBO J 7: 949–957. 18. Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885–890. 19. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, et al. (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733–736. 20. Hardy J (2006) A hundred years of Alzheimer’s disease research. Neuron 52: 3– 13. 21. Muller T, Meyer HE, Egensperger R, Marcus K (2008) The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer’s disease. Prog Neurobiol 85: 393–406. 22. Beckett C, Nalivaeva NN, Belyaev ND, Turner AJ (2012) Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24: 402–409. 23. Pardossi-Piquard R, Checler F (2012) The physiology of the ß-amyloid precursor protein intracellular domain AICD. J Neurochem 120 (Suppl. 1): 109–124. 24. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83: 4044–4048. 25. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, et al. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084–6089. 26. Tsuboi Y (2009) Clinical, pathological, and genetic characteristics of frontotemporal dementia and parkinsonism linked to chromosome 17 with mutations in the MAPT and PGRN. Brain Nerve 61: 1285–1291. 27. Iqbal K, Liu F, C.-X G, Grundke-Iqbal I (2010) Tau in Alzheimer Disease and related tauopathies. Curr Alzheimer Res 7: 656–664. 28. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316: 750–754. 29. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, et al. (2010) Tau reduction prevents Abeta-induced defects in axonal transport. Science 330: 198– 200. 30. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, et al. (2011) Tau- induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant. J Neurosci 31: 2511– 2525. 31. Ogata J, Budzilovich GN, Cravioto H (1972) A study of rod-like structures (Hirano bodies) in 240 normal and pathological brains. Acta Neuropathol 21: 61–67. 32. Fu Y, Ward J, Young HF (1975) Unusual, rod-shaped cytoplasmic inclusions (Hirano bodies) in a cerebellar hemangioblastoma. Acta Neuropathol 31: 129– 135. 33. Mori H, Tomonaga M, Baba N, Kanaya K (1986) The structure analysis of Hirano bodies by digital processing on electron micrographs. Acta Neuropathol 71: 32–37. 34. Hirano A, Dembitzer HM, Kurland LT, Zimmerman HM (1968) The fine structure of some intraganlionic alterations. J Neuropathol Expt Neurol 27: 167– 182. 35. Galloway PG, Perry G, Kosik KS, Gambetti P (1987) Hirano bodies contain tau protein. Brain Res 403: 337–340. 36. Laas R, Hagel C (1994) Hirano bodies and chronic alcoholism. Neuropathol Appl Neurobiol 20: 12–21. 37. Martinez-Saez E, Gelpi E, Rey M, Ferrer I, Ribalta T, et al. (2011) Hirano body - rich subtypes of Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol. 38. Galloway PG, Perry G, Gambetti P (1987) Hirano body filaments contain actin and actin-associated proteins. J Neuropathol Exp Neurol 46: 185–199. 39. Goldman JE (1983) The association of actin with Hirano bodies. J Neuropathol Exp Neurol 42: 146–152. 40. Schochet SS, Jr., McCormick WF (1972) Ultrastructure of Hirano bodies. Acta Neuropathol 21: 50–60. 41. Izumiyama N, Ohtsubo K, Tachikawa T, Nakamura H (1991) Elucidation of three-dimensional ultrastructure of Hirano bodies by the quick-freeze, deep-etch and replica method. Acta Neuropathol 81: 248–254. 42. Maselli AG, Davis R, Furukawa R, Fechheimer M (2002) Formation of Hirano bodies in Dictyostelium and mammalian cells induced by expression of a modified form of an actin cross-linking protein. J Cell Sci 115: 1939–1952. 43. Davis RC, Furukawa R, Fechheimer M (2008) A cell culture model for investigation of Hirano bodies. Acta Neuropathol 115: 205–217. Hirano Bodies Protect against Cell Death 44. Ha S, Furukawa R, Stramiello M, Wagner JJ, Fechheimer M (2011) Transgenic mouse model for the formation of Hirano bodies. BMC Neurosci 12: 97. 45. Munoz DG, Wang D, Greenberg BD (1993) Hirano bodies accumulate C- terminal sequences of beta-amyloid precursor protein (beta-APP) epitopes. J Neuropathol Exp Neurol 52: 14–21. 46. Maselli AG, Furukawa R, Thomson SAM, Davis RC, Fechheimer M (2003) Formation of Hirano bodies induced by expression of an actin cross-linking protein with a gain of function mutation. Eucaryot Cell 2: 778–787. 47. Ha S, Furukawa R, Fechheimer M (2011) Association of AICD and Fe65 with Hirano bodies reduces transcriptional activation and initiation of apoptosis. Neurobiol Aging 32: 2287–2298. 48. Lu DC, Soriano S, Bredesen DE, Koo EH (2003) Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem 87: 733–741. 49. Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, et al. (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels – proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2: 231–238. 50. Bretteville A, Ando K, Ghestem A, Loyens A, Begard S, et al. (2009) Two- dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes. PLoS One 4: e4843. 51. Gibson PH (1978) Light and electron microscopic observations on the relationship between Hirano bodies, neuron and glial perikarya in the human hippocampus. Acta Neuropathol (Berl) 42: 165–171. 52. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W (2011) Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphoryla- tion in primary culture. Cell Death Dis 2: e167. 53. Kinoshita A, Whelan CM, Berezovska O, Hyman BT (2002) The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277: 28530–28536. 54. Fath T, Eldenmu¨ller J, Brandt R (2002) Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer’s disease. J Neurosci 22: 9733–9741. 55. Eidenmu¨ller J, Fath T, Maas T, Pool M, Sontag E, et al. (2001) Phosphorylation- mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem J 357: 759–767. 56. Cao X, Su¨dhof TC (2004) Dissection of amyloid-beta precursor protein- dependent transcriptional transactivation. J Biol Chem 279: 24601–14611. 57. Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, et al. (2006) Presenilin-dependent gamma-secretase-mediated control of p53-associat- ed cell death in Alzheimer’s disease. J Neurosci 26: 6377–6385. 58. Tang Y, Luo J, Zhang W, Gu W (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827–839. 59. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, et al. (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841–851. 60. Sykes SM, Stanek TJ, Frank A, Murphy ME, McMahon SB (2009) Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem 284: 20197–20205. 61. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733–1737. 62. Niedowicz DM, Nelson PT, Murphy MP (2011) Alzheimer’s disease: Pathological mechanisms and recent insights. Curr Neuropharm 9: 674–684. 63. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698–712. 64. Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ (2001) The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 276: 40288– 40292. 65. Cupers P, Orlans I, Craessarts K, Annaert W, De Strooper B (2001) The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma- secretase is rapidly degraded but distributes partially in a nuclear fraction of neurons in culture. J Neurochem 78: 1168–1178. 66. Weidemann A, Eggert S, Reinhard FBM, Vogel M, Paliga K, et al. (2002) A novel e-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 41: 2825–2835. 67. Ren Z, Schenk D, Basi GS, Shapiro IP (2007) Amyloid ß-protein precursor juxtamembrain domain regulates specificty of c-secretase-dependent cleavages. J Biol Chem 48: 35350–33560. 68. Yamasaki A, Eimer S, Okochi M, Smialowska A, Kaether C, et al. (2006) The GxGD motif of presenilin contributes to catalytic function and substrate identification of c-secretase. J Neurosci 26: 3821–3828. 69. Zhang H, Ma Q, Zhang Y-w, Xu H (2012) Proteolytic processing of the Alzheimer’s ß-amyloid precursor protein. J Neurochen, 120: 9–21. 70. Perl DP (2010) Neuropathology of Alzheimer’s disease. Mt Sinai J Med 77: 32– 42. 71. Yokoo H, Oyama T, Hirato J, Sasaki A, Nakazato Y (1994) A case of Pick’s disease with unusual neuronal inclusions. Acta Neuropathol (Berl) 88: 604-. PLOS ONE | www.plosone.org 10 September 2012 | Volume 7 | Issue 9 | e44996